Company Overview of MOTUS THERAPEUTICS, INC.
MOTUS THERAPEUTICS, INC., a biopharmaceutical company, develops peptide therapeutics for the treatment of gastrointestinal (GI) diseases. The company’s product candidate, relamorelin, is a potent, ghrelin peptide agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. Its relamorelin is derived from the natural ghrelin sequence that targets the receptor for ghrelin, which is a naturally occurring hormone that plays a critical role in GI motility, digestion, and the absorption of nutrients. MOTUS THERAPEUTICS, INC. was formerly known as Rhythm Pharmaceuticals, Inc. and changed its name to MOTUS THERAPEUTICS, INC. in September 2014...
855 Boylston Street
Boston, MA 02116
Founded in 2008
Key Executives for MOTUS THERAPEUTICS, INC.
Chief Executive Officer and Director
Founder and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2017.
MOTUS THERAPEUTICS, INC. Key Developments
Rhythm Names Hunter Smith as New Chief Financial Officer
Aug 2 17
Rhythm named Hunter Smith as its new chief financial officer effective immediately. Smith has more than 20 years of global finance and management experience across multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. He joins the company from Celgene Corporation, where he served as vice president, Finance and chief financial officer of the company's Inflammation and Immunology Business Unit.
Rhythm Pharmaceuticals Inc. Announces Expansion of Phase Ii Obesity Trial
May 17 17
Rhythm Pharmaceuticals Inc. announced the expansion of its Phase II clinical trials of setmelanotide to the treatment of Bardet Biedl syndrome (BBS) obesity. Setmelanotide is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. This initial study is an open-label, Phase II clinical trial of setmelanotide for the treatment of BBS obesity. The clinical trial will evaluate the safety and efficacy of setmelanotide administered once daily by subcutaneous injection in patients with BBS obesity. Setmelanotide is a potent, first-in-class MC4R agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. The critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects along this pathway result in early-onset and severe obesity.
Rhythm Pharmaceuticals Names David Meeker as Chairman
Apr 11 17
Rhythm Pharmaceuticals has appointed David Meeker as chairman of the board. Currently, Meeker serves at Genzyme as its president and chief executive officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|